Intimation of appointment of Secretarial Auditors
Awaiting price reaction for this filing.
Aurobindo Pharma's board approved its standalone and consolidated audited financial results for Q4 and FY ended March 31, 2025. Statutory auditor Deloitte Haskins & Sells issued an unmodified (clean) opinion on the results. The board appointed M/s. MRR & Associates, a peer-reviewed firm of company secretaries, as Secretarial Auditors for five years (FY2025-26 to FY2029-30), subject to shareholder approval at the upcoming AGM. The board also approved seeking shareholder approval via postal ballot to enhance the company's existing limits under Section 186 of the Companies Act, which governs loans, investments, and guarantees to other entities.
This is largely a routine governance update. The clean audit opinion from Deloitte is reassuring for shareholders. The Section 186 limit expansion will give the company more flexibility to lend to or invest in subsidiaries and other entities, while the secretarial auditor appointment is a standard regulatory compliance requirement.